Related Experiment Video
Updated: May 10, 2025
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Novel approaches in antihypertensive pharmacotherapeutics
Sidar Copur1, Alexandru Burlacu2,3, Mehmet Kanbay4
1Department of Internal Medicine, Division of Internal Medicine, Koç University School of Medicine, Istanbul, Turkey.
Insights
Novel pharmacotherapies are emerging to address suboptimal hypertension management, particularly for resistant cases. These new treatments target various pathways and hold promise for improving patient outcomes in cardiovascular health.
Area of Science:
- Cardiology
- Pharmacology
- Internal Medicine
Background:
- Hypertension management is often suboptimal despite numerous available medications.
- Resistant hypertension affects about 10% of patients, leading to significant morbidity and mortality.
Purpose of the Study:
- To evaluate novel therapeutic approaches for managing hypertension.
- To explore emerging pharmacotherapies for improved blood pressure control.
Main Methods:
- Review of recent pharmacotherapeutic strategies for hypertension.
- Analysis of novel agents targeting diverse pathophysiological mechanisms.
Main Results:
- Several novel agents are under investigation, including aldosterone synthetase inhibitors, RNA-based therapies (antisense oligonucleotides, small-interfering RNA), atrial natriuretic peptide analogs, dual endothelin antagonists, intestinal sodium-hydrogen exchanger-3 inhibitors, compound 17b, and nonsteroidal mineralocorticoid receptor antagonists.
- These novel approaches target various pathophysiological pathways implicated in hypertension.
Conclusions:
- The field of hypertension pharmacotherapy is rapidly evolving with promising new agents.
- These novel treatments have the potential to significantly improve clinical outcomes for patients with hypertension.
Purpose Of Review:
The management of hypertension remains suboptimal despite the widespread use of multiple antihypertensive medication groups. We hereby aim to evaluate the novel therapeutic approaches for the management of hypertension.
Recent Findings:
As the decline in SBP and/or DBP is associated with a significant decline in major adverse cardiovascular events and all-cause mortality, the optimal management of hypertension is at most importance. The high prevalence of resistant hypertension, approximately 10% of hypertensive population, remains a major concern associated with high morbidity and mortality. Recently, multiple novel pharmacotherapeutic approaches have been implicated in the management of hypertension on various pathophysiological mechanisms, including aldosterone synthetase inhibitors, RNA-based therapies such as antisense oligonucleotides and small-interfering RNA, atrial natriuretic peptide analogs, dual endothelin antagonists, intestinal sodium-hydrogen exchanger-3 inhibitors, compound 17b and nonsteroidal mineralocorticoid receptor antagonists.
Summary:
Pharmacotherapeutic management options for hypertension is a growing field of research with potential clinical implications for multiple agents in upcoming years. Such novel approaches have the potential to improve clinical outcomes of hypertension management.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:25Antihypertensive Drugs: Direct Renin Inhibitors
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
01:23Antihypertensive Drugs: Vasodilators
01:16Antihypertensive Drugs: Action of Diuretics
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...